T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy

Kaplan, Henry G.; Malmgren, Judith A.; Atwood, Mary

doi:10.1111/j.1524-4741.2009.00789.x

Cited by 85 publications

(64 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, patients with TNBC may achieve increased short-term DFS rates. In brief, TNBC patients have a poorer OS time and tend to relapse sooner compared with patients with other breast cancer subtypes (41). The present study reports that lymph node status is an effective prognostic parameter for TNBC patients, particularly for those that exhibit the N3 stage of disease; however, the effect of stages of disease is decreased.…”

Section: Patients --------------------------------------------------mentioning

confidence: 54%

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide

Sun

Liu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the association between the clinicopathological and demographic factors, and the survival time of patients with triple-negative breast cancer (TNBC) in China. The patients had received adjuvant chemotherapy consisting of 5-fluorouracil, epirubicin and cyclophosphamide (FEC; 500 mg/m 2 cyclophosphamide, day 1; 75 mg/m 2 epirubicin, day 1; 500 mg/m 2 5-fluorouracil, days 1 and 8; every 3 weeks, for at least 4 cycles). The clinicopathological and demographic factors affecting the outcome of the patients with TNBC that received adjuvant FEC chemotherapy were evaluated. Within these variables, the overall survival (OS) and disease-free survival (DFS) times were analyzed using the log-rank test, which was constructed using the multivariate Cox proportional hazards regression model and Kaplan-Meier analysis. Additionally, Spearman's χ 2 test was used to analyze categorical variables. In the univariate statistical analysis, the significant risk factors for TNBC patient survival were the stage of disease and lymph node status, which were associated with the OS and DFS, and the total number of pregnancies, which was associated with the DFS. In the multivariate Cox proportional hazard model, lymph node status was an independent prognostic indicator of OS [P<0.001; hazard ratio (HR), 1.996; 95% confidence interval (CI), 1.465-2.720] and DFS (P<0.001; HR, 1.824; 95% CI, 1.315-2.531). By the Kaplan-Meier method, the stage of disease and lymph node status demonstrated a significant effect on OS and DFS. Patients with the lymph node status N3 and stage III disease possessed a poor prognosis and survival. An association between lymph node status and the tumor recurrence and mortality rate was identified. The area under the curves of the lymph node status for TNBC recurrence and mortality were 0.676 (P=0.002) and 0.685 (P=0.001), respectively. Additionally, the number of pregnancies was associated with tumor size, lymph node status and stages of disease. Lymph node status is an independent prognostic indicator of OS and DFS to TNBC patients with FEC adjuvant chemotherapy. IntroductionBreast cancer is one of the most common malignancies and leading causes of cancer-associated mortalities among females (1). Based on DNA microarray techniques, breast cancer is classified into five subtypes: Luminal A; luminal B; normal breast-like; human epidermal growth factor receptor 2 (HER2/neu) overexpressing; and basal-like (2). The subtype that is immunohistochemically characterized by the lack of expression of the estrogen receptor (ER), progesterone receptor (PR) and HER2 is defined as triple negative breast cancer (TNBC) (3).TNBC, which accounts for 10-15% of breast cancers, is considered to exhibit an aggressive clinical behavior and poor prognosis, due to the insensitivity of the cancer to endocrine and targeted therapy (4-12). Therefore, chemotherapy is a significant therapy for such cancers. The treatment options for TNBC include anthracyclines, taxanes, platinum and alkylating ...

show abstract

Section: Patients --------------------------------------------------mentioning

confidence: 54%

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide

Sun

Liu

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Till now, there is no effective therapy for TNBC (Anders et al, 2009;Ma et al, 2012). Although TNBC is sensitive to initial chemotherapy (Kaplan et al, 2009), it still shows a worse prognosis for DFS and OS than non-TNBC (Kim et al, 2006;Kaplan et al, 2008;Rakha et al, 2008). Thus, it is essential for researchers and clinicians to find a reliable prognostic factors and therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer

Wu¹,

Hu²,

Gao³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…TN and basal-like tumors have been characterized by several aggressive histopathological features, including high histological and nuclear tumor grade, large tumor size, elevated mitotic count, area of central fibrosis and necrosis, pushing margin of invasion, poor tubule formation, lymphocytic stromal response, and high nuclear-cytoplasmic ratio [9,16,[25][26][27][28][29][30]. The majority of TNBCs are invasive ductal carcinomas of no special type [31]; however, there are several other and mostly rare histological types that may frequently be TN.…”

Section: Histopathological Featuresmentioning

confidence: 99%

Triple-Negative Breast Cancer: Clinical and Histological Correlations

Elsawaf

Sinn²

2011

Breast Care

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen and progesterone receptors and the lack of HER2 expression or amplification. Much interest has recently been focused on these triple-negative (TN) subtypes because they may be aggressive and are more likely to recur and metastasize than other subtypes of breast cancer. TNBC accounts for approximately 10–24% of all breast cancer cases, and typically it occurs in younger patients and in patients with BRCA1 mutation. There is a substantial heterogeneity of TNBCs both at the morphological and the molecular level, but there are also common features, such as low tumor grade and accelerated tumor proliferation. Morphologically, TNBC may present as invasive ductal, metaplastic, medullary, apocrine, or other types. Molecularly, they are most frequently associated with a basal phenotype, but there is a distinct subgroup of cancers that are not of basal type and belong to the claudin-low or molecular-apocrine type. The basal phenotype is frequently associated with the loss of BRCA1.

show abstract

T1N0 Triple Negative Breast Cancer: Risk of Recurrence and Adjuvant Chemotherapy

Cited by 85 publications

References 20 publications

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide

Low Expression of Tyrosine-protein Phosphatase Nonreceptor Type 12 is Associated with Lymph Node Metastasis and Poor Prognosis in Operable Triple-negative Breast Cancer

Triple-Negative Breast Cancer: Clinical and Histological Correlations

Contact Info

Product

Resources

About